AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05794438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Approach Bias Modification
Description: In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
Study NCT05794438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Approach Bias Modification
Description: In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
Study NCT06343051 — intervention group
Intervention type: DEVICE
Intervention: USCOM
Description: Device that measures how much blood is being pumped in and out of the heart.
Study NCT05955352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal warm compression Technique
Description: There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
Study NCT06216522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Sesame Oil
Description: 5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours
Study NCT06216522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid paraffin oil
Description: 5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
Study NCT05618548 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
Study NCT06352372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)
Description: The proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills.
Study NCT05453825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: navicixizumab+paclitaxel
Description: navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
Study NCT05453825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: navicixizumab+irinotecan
Description: navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
Study NCT05453825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: navicixizumab monotherapy
Description: navicixizumab 3 mg/kg Q2W
Study NCT06347094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Plan
Description: Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet
Study NCT06347094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (Poly)phenol Challenge Test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets
Study NCT06347094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Dietary Advice
Description: Prescription of balanced dietary plans
Study NCT01175525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CROMOLYN
Description: Cromolyn 200mg (dissolved in water) given 4 times a day
Study NCT01175525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-folinic acid
Description: Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
Study NCT06509126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-folinic acid
Description: Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
Study NCT05129319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prabotulinumtoxinA
Description: Injection of glabellar rhytids
Study NCT05721131 — intervention group
Intervention type: DEVICE
Intervention: NC° Thermometer (Gen 3)
Description: The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
Study NCT06540638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based education program
Description: In a pre-operative assessment, 1-30 days prior to their scheduled surgery, patients will be asked to participate in our web-based educational program. The content of our e-module included: introduction to brain health, surgery, and delirium, causes and risk factors, modifiable risk factors, and delirium prevention. The program will be delivered on a research laptop/iPad at the clinic. The entire program, including pre- and post-education questionnaires and satisfaction survey should take about 20 minutes to complete.
Study NCT05953688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet
Study NCT05164575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise
Description: Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
Study NCT05164575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management strategies
Description: Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
Study NCT06162650 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy, 5×5 Gy.
Study NCT06162650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
Study NCT06511336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
Study NCT06511336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
Study NCT06511336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
Study NCT06048510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnant women
Description: Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin.
Study NCT04231708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine + Hydrocortisone
Description: Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
Study NCT04231708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: 10Hz rTMS over the left dlPFC
Study NCT04231708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose (inside capsule)
Study NCT04231708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose (inside capsule)
Study NCT04231708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: inactive stimulation over the left dlPFC
Study NCT04231708 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: inactive stimulation over the left dlPFC
Study NCT04953390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo hearing aid
Description: Commercially available hearing aid with three different microphone settings: DIR1, DIR2, and DIR3
Study NCT04953390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak hearing aid with multiple directionality settings, adjustable via a mobile app
Description: Commercially available hearing aid with multiple directionality settings which will be adjustable by user via a mobile app during a home trial period.
Study NCT05698238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA9hu-1
Description: Humanized monoclonal antibody to human carbonic anhydrase IX
Study NCT05554068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
Study NCT06121154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F questionnaire
Description: The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia.
Study NCT06121154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gait speed
Description: Low gait speed was defined as walking below than 0.8 meters per second.
Study NCT06121154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The chair rise test
Description: the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
Study NCT05170256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
Study NCT06121154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Grip strength
Description: Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females
Study NCT06121154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual analog scale
Description: The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
Study NCT05049759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confident, Active and Happy Youth
Description: The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
Study NCT05047055 — intervention group
Intervention type: DRUG
Intervention: Isoniazid
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
Study NCT05047055 — intervention group
Intervention type: DRUG
Intervention: Rifampicin
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
Study NCT05047055 — intervention group
Intervention type: DRUG
Intervention: Pyrazinamide
Description: Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
Study NCT05047055 — intervention group
Intervention type: DRUG
Intervention: Ethambutol
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
Study NCT05047055 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
Study NCT05736341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
Study NCT05736341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
Study NCT06008574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmDTx-PCSP
Description: Step-by-step program modules including meditation training and other activities relevant for people living with cancer
Study NCT06008574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AmDTx-2048
Description: Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value.
Study NCT06008574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
Study NCT06008574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
Study NCT06490250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day
Study NCT06490250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise
Description: The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
Study NCT06029309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1.
Study NCT06029309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15
Study NCT06579066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Capsule
Description: Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
Study NCT06579066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
Study NCT05141071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 5mg Tab
Description: Ivabradine will be administrated enterally
Study NCT05141071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of saline will be administrated enterally
Study NCT05213559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheat biscuit enriched with plant proteins
Description: Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
Study NCT05213559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common wheat biscuit
Description: Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
Study NCT05824312 — intervention group
Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor drugs.
Description: TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
Study NCT04502758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture TMS Therapy System w/Theta Burst Stimulation
Description: During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
Study NCT05724979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZP-binding
Description: The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region